Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Thromb Haemost ; 1(10): 2140-8, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14521596

RESUMEN

A prospective randomized double-blind study was performed to determine the effects of three colloids, Haemaccel, Gelofusine and albumin, and also saline on platelet activation, platelet aggregation (induced by adenosine diphosphate (ADP), epinephrine, collagen) platelet agglutination by ristocetin and other hemostatic variables in 55 patients undergoing primary unilateral total hip replacement. The fluids were administered according to normal clinical practice and assessments were made immediately before, at the end, and 2 h after the end of surgery. Surgery was accompanied by thrombin generation (increases in thrombin/antithrombin III complex, prothrombin F1 +2 fragment) platelet activation (betaTG) and compromised coagulation. Generally, the platelet activation appeared to result in platelet desensitization and brought about a persistent reduction in platelet aggregation to ADP and epinephrine, irrespective of the fluid used. Additionally, Haemaccel and Gelofusine inhibited ristocetin-induced platelet agglutination and albumin inhibited collagen-induced platelet aggregation. Gross inhibitory effects of Haemaccel that had been predicted from an earlier in vitro study did not occur. Particular fluids had selective additional effects on the hemostatic system. Albumin infusion served to maintain plasma albumin at normal concentrations postsurgery. The two gelatin preparations, Haemaccel and Gelofusine, maintained plasma viscosity. All three colloids led to a transient increase in activated partial thromboplastin time postsurgery and also a transient fall in the concentration of factor VIII, which were accompanied by a transient increase in bleeding time, but there was no measurable increase in blood loss. Inhibition of platelet aggregation by certain colloids may provide additional protection against the increased thrombotic risk in patients following major surgery.


Asunto(s)
Artroplastia de Reemplazo de Cadera/métodos , Coagulación Sanguínea/efectos de los fármacos , Plaquetas/efectos de los fármacos , Hemostasis/efectos de los fármacos , Agregación Plaquetaria , Adenosina Difosfato/metabolismo , Anciano , Albúminas/uso terapéutico , Antibacterianos/uso terapéutico , Antitrombina III/biosíntesis , Tiempo de Sangría , Sangre/metabolismo , Coloides/metabolismo , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Epinefrina/biosíntesis , Epinefrina/farmacología , Femenino , Gelatina/química , Gelatina/uso terapéutico , Hematócrito , Humanos , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/biosíntesis , Sustitutos del Plasma/uso terapéutico , Activación Plaquetaria , Poligelina/uso terapéutico , Estudios Prospectivos , Precursores de Proteínas/biosíntesis , Protrombina/biosíntesis , Ristocetina/farmacología , Ristocetina/uso terapéutico , Cloruro de Sodio/farmacología , Succinatos/uso terapéutico , Trombina/biosíntesis , Factores de Tiempo , beta-Tromboglobulina/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA